聚乙二醇干扰素联合富马酸替诺福韦治疗HBeAg阴性慢性乙型肝炎的临床研究  

Clinical Study of Pegylated Interferon Combined with Tenofovir Fumarate in the Treatment of HBeAg Negative Chronic Hepatitis B

作　　者：李金伟 LI Jinwei(Department of Hepatology Ⅱ,Qiqihar Seventh Hospital,Qiqihar,Heilongjiang Province,161002 China)

机构地区：[1]齐齐哈尔市第七医院肝病二科,黑龙江齐齐哈尔161002

出　　处：《世界复合医学》2023年第3期164-166,170,共4页World Journal of Complex Medicine

基　　金：齐齐哈尔市科技计划创新激励项目(CSFGG-2021005)。

摘　　要：目的探讨应用聚乙二醇干扰素联合富马酸替诺福韦治疗乙肝e抗原(hepatitis B e antigen,HbeAg)阴性慢性乙型肝炎,对肝功能指标的影响。方法选取2021年1月—2022年1月来齐齐哈尔市第七医院就诊的HBeAg阴性的慢性乙型肝炎患者60例,根据随机数表法分成3组,A组为单用富马酸替诺福韦治疗乙型肝炎,B组为单用聚乙二醇干扰素治疗乙型肝炎,C组为富马酸替诺福韦联合聚乙二醇干扰素乙型肝炎,观察聚乙二醇干扰素联合富马酸替诺福韦治疗慢性乙型肝炎的临床效果。结果治疗12个月后,3组患者的谷草转氨酶(aspartate aminotransferase,AST)和谷丙转氨酶(alanine aminotransferase,ALT)水平比较,C组改善明显优于B组、A组,差异有统计学意义(P<0.05)。治疗12个月后,3组患者生化指标比较,C组患者的乙肝病毒(HBV)DNA转阴率、乙肝e抗原(HbeAg)转阴率和ALT复常率均显著高于A组及B组(70.00%、75.00%、85.00%vs 30.00%、35.00%、40.00%vs 40.00%、30.00%、45.00%),差异有统计学意义(χ^(2)=6.964,9.777,9.910,P<0.05)。结论应用聚乙二醇干扰素同时配伍富马酸替诺福韦药物对HBeAg阴性慢性乙型肝炎临床疗效十分显著,药物对患者的稳定和安全性极高,值得临床广泛推广应用。Exploring the effect of polyethylene glycol interferon combined with tenofovir fumarate in the treatment of hepatitis B e antigen(HBeAg)negative chronic hepatitis B on liver function indicators.Methods 60 patients with HBeAg-negative chronic hepatitis B who came to Qiqihar Seventh Hospital from January 2021 to January 2022 were selected and divided into 3 groups according to random number table method.Group A was treated with tenofovir fumarate alone for hepatitis B,Group B was treated with pegylated interferon alone for hepatitis B,and Group C was treated with tenofovir fumarate combined with pegylated interferon for hepatitis B.The clinical effects of pegylated interferon combined with tenofovir fumarate in the treatment of chronic hepatitis B were observed.Results After 12 months of treatment,the levels of aspartate aminotransferase(AST)and alanine aminotransferase(ALT)in 3 groups were compared,and the improvement in group C was significantly better than that in group B and group A,the difference was statistically significant(P<0.05).After 12 months of treatment,the comparison of biochemical indexes among the three groups,the hepatitis B virus(HBV)DNA negative conversion rate,Hepatitis B e antigen(HbeAg)negative conversion rate and ALT normalizing rate in group C were significantly higher than those in groups A and B(70.00%,75.00%,85.00%vs 30.00%,35.00%,40.00%vs 40.00%,30.00%,45.00%),the difference was statistically significant(χ^(2)=6.964,9.777,9.910,P<0.05).Conclusion The clinical efficacy of pegylated interferon combined with tenofovir fumarate in the treatment of HBeAg negative chronic hepatitis B is very significant,and the drug is highly stable and safe for patients,which is worthy of wide clinical application.

关 键 词：聚乙二醇干扰素 富马酸替诺福韦 慢性乙型肝炎 转阴率 临床效果 

分 类 号：R4[医药卫生—临床医学]